1. Home
  2. MCBS vs BWAY Comparison

MCBS vs BWAY Comparison

Compare MCBS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Inc.

HOLD

Current Price

$31.78

Market Cap

816.1M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$14.91

Market Cap

674.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCBS
BWAY
Founded
2006
2003
Country
United States
Israel
Employees
N/A
129
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
816.1M
674.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MCBS
BWAY
Price
$31.78
$14.91
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$33.00
$13.25
AVG Volume (30 Days)
53.2K
133.6K
Earning Date
04-24-2026
05-13-2026
Dividend Yield
3.63%
N/A
EPS Growth
4.76
N/A
EPS
0.77
N/A
Revenue
N/A
N/A
Revenue This Year
$36.78
$309.69
Revenue Next Year
$2.44
$26.21
P/E Ratio
$40.53
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$24.53
$10.01
52 Week High
$33.67
$26.63

Technical Indicators

Market Signals
Indicator
MCBS
BWAY
Relative Strength Index (RSI) 55.02 40.14
Support Level $30.72 $14.56
Resistance Level $33.38 $16.63
Average True Range (ATR) 0.80 0.64
MACD -0.17 -0.19
Stochastic Oscillator 40.77 2.01

Price Performance

Historical Comparison
MCBS
BWAY

About MCBS MetroCity Bankshares Inc.

MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: